[en] Valvular heart disease (VHD) represents a significant burden within the spectrum of cardiovascular diseases. In recent years, there has been a great interest in finding medical treatments able to slow the progression ofVHD. The negative results of several large randomized trials failing to demonstrate a benefit of such therapies, has led to a decrease of interest in this field. However, finding a medical treatment capable of preventing VHD progression is still a hot topic, due to the important clinical implications. We believe that the jury is still out on the debate about the role of statin therapy in VHD, considering also recently published studies providing new information with future implications for the treatment of this disease process. This article gives an overview of the published evidence about the role of hydroxymethylglutaryl coenzyme-A reductase inhibitors on delaying progressive valve dysfunction. A preventive therapy, which could influence not only the haemodynamic progression of valve disease, but also the cardiovascular outcome, is warranted. Large, prospective, randomized trials are needed to properly evaluate the role of statins in the early stages of valvular heart disease.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Antonini-Canterin, Francesco
Mateescu, Anca D.
Nicolosi, Gian Luigi
Ginghina, Carmen
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Imagerie cardiaque fonctionnelle par échographie
Cosyns, Bernard
Popescu, Bogdan Alexandru
Language :
English
Title :
The role of statin treatment in valvular heart disease: is the jury still out?
Publication date :
2013
Journal title :
Acta Cardiologica
ISSN :
0001-5385
eISSN :
1784-973X
Publisher :
Association Royale des Sociétés Scientifiques Medicales Belges/Koninklijke Vereniging van de Belgische Medische Wetenschappelijke Genootschappen, Bruxelles, Belgium
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005-11.
Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, DeBonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease. Eur Heart J 2012; 33: 2451-96.
Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24: 1231-43.
Faggiano P, Antonini-Canterin F, Erlicher A, Romeo C, Cervesato E, Pavan D, Piazza R, Huang G, Nicolosi GL. Progression of aortic valve sclerosis to aortic stenosis. Am J Cardiol 2003; 91: 99-101.
Nightingale AK, Horowitz JD. Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk. Heart 2005; 91: 1389-93.
Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003; 107: 2181-4.
Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe asymptomatic aortic stenosis. N Engl J Med 2000; 343: 611-7.
Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of degenerative valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844-53.
Nassimiha D, Aronow WS, Ahn C, Goldman ME. Association of coronary risk factors with progression of valvular aortic stenosis in older persons. Am J Cardiol 2001; 87: 1313-4.
Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001; 104: 1927-32.
Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T, Seino Y, Nagoh N, Kayaba K, Yamada S, Matsuo H. Correlation between lipoprotein (a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76: 928-32.
Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005; 91: 806-10.
Roosens B, Bala G, Droogmans S, Van Camp G, Breyne J, Cosyns B. Animal models of organic heart valve disease. Int J Cardiol 2013; 165: 398-409.
Ortlepp JR, Hoffmann R, Ohme F, Lauscher J, Bleckmann F, Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001; 85: 635-8.
Novaro GM, Sachar R, Pearce GL, Sprecher DL, Griffin BP. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 2003; 108: 1804-8.
Thanassoulis G, Campbell C, Owens D, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, BudoffMJ, Harris TB, Malhotra R, O'Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, Kälsch H, Mühleisen TW, Nöthen MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O'Donnell CJ, Post WS: CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368: 503-12.
Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis inolder persons. Am J Cardiol 2001; 88: 693-5.
Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001; 104: 2205-9.
Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002; 40: 1723-30.
Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004; 110: 1291-5.
Antonini-Canterin F, Hirsu M, Popescu BA, Leiballi E, Piazza R, Pavan D, Ginghinǎ C, Nicolosi GL. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008; 102: 738-42.
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389-97.
Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-56.
Dichtl W, Alber HF, Feuchtner GM, Hintringer F, Reinthaler M, Bartel T, Süssenbacher A, Grander W, Ulmer H, Pachinger O, Müller S. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am J Cardiol 2008; 102: 743-8.
Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER trial). Circulation 2010; 121: 306-14.
Moura L, Ramos S, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49: 554-61.
Van der Linde D, Yap SC, Van Dijk AP, Budts W, Pieper PG, van der Burgh PH, Mulder BJ, Witsenburg M, Cuypers JA, Lindemans J, Takkenberg JJ, Roos-Hesselink JW. Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS trial). Am J Cardiol 2011; 108: 265-71.
Farivar RS, Cohn LH. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg 2003; 126: 969-75.
Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 2003; 41: 893-904.
Briand M, Pibarot P, Despres JP, Voisine P, Dumesnil JG, Dagenais F, Mathieu P. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 2006; 114(1 Suppl): I512-7.
Rajamannan NL, Evans F, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O'Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process. Circulation 2011; 124: 1783-91.
Lorusso R, Corradi D, Maestri R, Bosio S, Curulli A, Beghi C, Gerometta P, Russo C, Gelsomino S, Moreo A, De Cicco G, Rosano G, Volterrani M. Atorvastatin attenuates post-implant tissue degeneration of cardiac prosthetic valve bovine pericardial tissue in a subcutaneous animal model. Int J Cardiol 2010; 141: 68-74.
Nollert G, Miksch J, Kreuzer E, Reichart B. Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. J Thorac Cardiovasc Surg 2003; 126: 965-8.
David TE, Ivanov J. Is degenerative calcification of the native aortic valve similar to calcification of bioprosthetic heart valves? J Thorac Cardiovasc Surg 2003; 126: 939-41.
Antonini-Canterin F, Zuppiroli A, Popescu BA, Granata G, Cervesato E, Piazza R, Pavan D, Nicolosi GL. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003; 92: 1479-82.
Gring CN, Houghtaling P, Novaro GM, Roselli E, Smedira N, Banbury M, Blackstone E, Griffin BP. Preoperative cholesterol levels do not predict explant for structural valve deterioration in patients undergoing bioprosthetic aortic valve replacement. J Heart Valve Dis 2006; 15: 261-8.
Kulik A, Masters RG, Bedard P, Hendry PJ, Lam BK, Rubens F, Mesana TG, Ruel M. Postoperative lipid-lowering therapy and bioprosthesis structural valve deterioration: justification for a randomised trial? Eur J Cardiothorac Surg 2010; 37: 139-44.
Rajamannan NM, Antonini-Canterin F, Moura L, Zamorano JL, Rosenhek RA, Best PJ, Lloyd MA, Rocha-Goncalves F, Chandra S, Alfieri O, Lancellotti P, Tornos P, Baliga RR, Wang A, Bashore T, Ramakrishnan S, Spargias K, Shuvy M, Beeri R, Lotan C, Suwaidi JA, Bahl V, Pierard LA, Maurer G, Nicolosi GL, Rahimtoola SH, Chopra K, Pandian NG. Medical therapy for rheumatic heart disease: is it time to be proactive rather than reactive? Indian Heart J 2009; 61: 14-23.
Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev CI, Sebo TJ, Rosengart TK, Edwards WD, McCarthy PM, Bonow RO, Spelsberg TC. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 2005; 111: 3296-301.
Antonini-Canterin F, Leiballi E, Enache R, Popescu BA, Roşca M, Cervesato E, Piazza R, Ginghinǎ C, Nicolosi GL. Hydroxymethylglutaryl coenzyme-A reductase inhibitors delay the progression of rheumatic aortic valve stenosis: a long-term echocardiographic study. J Am Coll Cardiol 2009; 53: 1874-9.
Antonini-Canterin F, Moura LM, Enache R, Leiballi E, Pavan D, Piazza R, Popescu BA, Ginghina C, Nicolosi GL, Rajamannan NM. Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease. Circulation 2010; 121: 2130-6.
Hoffmann H, Frieler K, Schlattmann P, Hamm B, Dewey M. Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography. Eur Radiol 2010; 20: 2824-33.
Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005; 112: 1229-34.
Shetty R, Pibarot P, Audet A, Janvier R, Dagenais F, Perron J, Couture C, Voisine P, Després JP, Mathieu P. Lipid-mediated inflammation and degeneration of bioprosthetic heart valves. Eur J Clin Invest 2009; 39: 471-80.